Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results
Acq. announced
Director departure
Merger agrmnt [a]
Appointed director

VYNE Therapeutics Inc. (MNLO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update"
05/11/2023 8-K Quarterly results
Docs: "VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update"
05/01/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions"
03/09/2023 8-K Quarterly results
Docs: "VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update"
02/28/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule BRIDGEWATER, N.J., February 28, 2023 -- VYNE Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market on February 28, 2023, indicating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550 of the Nasdaq Listing Rules. According to the Notification Letter on Compliance, the staff of Nasdaq has determined that for the last 10 consecutive business days, from February 13, 2023 through February 27, 2023, the closing bid p..."
02/10/2023 8-K Quarterly results
01/17/2023 8-K Quarterly results
01/12/2023 8-K Results of Operations and Financial Condition, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure,...
11/10/2022 8-K Quarterly results
08/30/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events ...
08/12/2022 8-K Quarterly results
Docs: "VYNE Therapeutics Reports Second Quarter 2022 Financial Results"
08/10/2022 8-K Quarterly results
07/27/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
05/17/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/07/2022 8-K Changes in Registrant's Certifying Accountant, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Letter from PricewaterhouseCoopers LLP",
"VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis"
03/30/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis"
03/17/2022 8-K Quarterly results
Docs: "VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update"
03/15/2022 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "VYNE Therapeutics Inc. 520 U.S Highway 22, Suite 204 Bridgewater, New Jersey 08807",
"WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes to buy from the Company, up to Thirty Million Dollars of the Company’ s common stock, $0.0001 par value per share . The shares of Common Stock to be purchased hereunder are referred to herein as the “ Purchase Shares .” NOW THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Investor hereby agree as follows: 1. CERTAIN DEFINITIONS. For purposes of this Agreement, the following terms shall have the following meanings: “ Accelerated Purchase Date ” means, with respect to any Accelerated Purchase made...",
"REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT , dated as of March 15, 2022, is entered into by and between VYNE THERAPEUTICS, INC., a Delaware corporation , and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company . Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof . WHEREAS: A. Upon the terms and subject to the conditions of the Purchase Agreement, the Company has agreed to issue to the Investor, and the Investor has agreed to purchase, up to Thirty Million Dollars of the Company’ s common stock, par value $0.0001 per share , pursuant to the Purchase Agreement , and the Company has agreed to issue to the Inve..."
03/08/2022 8-K Quarterly results
03/07/2022 8-K Quarterly results
03/04/2022 8-K Quarterly results
01/19/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis"
01/13/2022 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial State...
Docs: "CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT BOTH IS NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION",
"VYNE Therapeutics Divests Topical Minocycline Assets"
01/05/2022 8-K Investor presentation
Docs: "INVESTOR PRESENTATION January 2022 Forward Looking Statements This"
11/10/2021 8-K Investor presentation, Quarterly results
Docs: "VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update",
"INVESTOR PRESENTATION November 2021 Forward Looking Statements This"
11/04/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass and Overall Skin Repair Outcomes in Preclinical Study"
10/26/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflammatory Cytokines in Preclinical Studies"
10/19/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis"
09/03/2021 8-K Quarterly results
08/12/2021 8-K Quarterly results
08/12/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM",
"CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM",
"Explanatory Note The COVID-19 pandemic and government measures taken in response to the pandemic have had a negative impact on the Company's operations. Access to healthcare providers has been limited, which has negatively impacted sales and the Company's ability to execute its commercial strategy with respect to AMZEEQ and ZILXI. In addition, the commercial launches of both AMZEEQ and ZILXI have been negatively impacted by unfavorable payor decisions in March 2021 on product pricing. These conditions have impaired the Company's ability to generate revenue consistent with internal forecasts, which has had a negative impact on its financial condition and liquidity subsequent to the issuance of our Form 10-K on March 4, 2021. As a result of these effects, Note 1 to the financial statements a..."
08/12/2021 8-K Quarterly results
Docs: "VYNE Therapeutics Reports Second Quarter 2021 Financial Results and Announces New Strategic Direction to Develop Treatments for Immunological and Inflammatory Diseases Company announced license agreement with In4Derm Limited for BETi platform earlier this morning",
"VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory Conditions with In4Derm Limited VYNE will have exclusive access to a library of new chemical entities",
"INVESTOR PRESENTATION August 2021 Exhibit 99.3 Forward Looking Statements 2 This"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy